Astellas Pharma Acquires Dynogen Research Facility

Astellas Pharma has acquired Dynogen Pharmaceuticals NC-based research facility. The research facility specializes in state-of-the-art preclinical studies for genitourinary disorders. Financial details were not disclosed.

“We’ve built an impressive clinical and preclinical pipeline through our unique understanding of the neuroscience underlying gastrointestinal and genitourinary disorders, leveraging that knowledge to generate strong intellectual property and utilizing that intellectual property to enable an aggressive in-licensing program,” said Lee R. Brettman, M.D., president and chief executive officer of Dynogen. “We’ve maximized the value of the North Carolina facility in this effort, and now will focus all of our efforts on advancing the development of our five clinical programs and our late-stage preclinical programs.”

“Dynogen has built a facility with first-class capabilities for evaluating the clinical potential of urological development candidates especially in the area of lower urinary tract disorders. The acquisition of this research facility will strengthen our capabilities in this key area,” said Isao Yanagisawa, Ph.D., senior corporate officer of Astellas Pharma.